Where is Alexion Pharmaceuticals located?

Where is Alexion Pharmaceuticals located?

Boston, Massachusetts
United States of America Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with severe and life-threatening rare disorders. Alexion’s global headquarters is in Boston, Massachusetts and its Center of Excellence is based in New Haven, Connecticut.

Is Alexion still in New Haven?

In the summer of 2018, Alexion Pharmaceuticals relocated its headquarters from New Haven to Boston. The company employs hundreds at its Center of Excellence at 100 College St.

Who owns Alexion Pharmaceuticals?

AstraZeneca
Alexion Pharmaceuticals/Parent organizations

When did Alexion go public?

Alexion develops drugs to treat rare diseases. Pharmaceutical companies that produce drugs to treat rare diseases that afflict fewer than 10,000 people can charge very high prices for these drugs. They must also spread the cost of research and development over fewer patients since the drugs are not widely used.

Is Alexion being acquired?

AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.

Was Alexion bought out?

AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission (FTC) review. Cambridge-based AstraZeneca (AZ) first announced its intention to buy out Alexion in December.

What happened to Alexion Pharmaceuticals?

AstraZeneca today completed the acquisition of Alexion Pharmaceuticals, Inc. The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca.

Who is CEO of Alexion?

Ludwig N. Hantson (Mar 2017–)
Alexion Pharmaceuticals/CEO
Ludwig N. Hantson, Ph. D., is Chief Executive Officer of Alexion. Dr. Hantson is an accomplished healthcare executive with more than 30 years of experience in the biopharmaceutical industry.

How much did AstraZeneca buy Alexion for?

AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals for $39 billion, in what would be the largest biopharma acquisition of 2020.

Where is Pfizer’s headquarters?

New York, NY
Pfizer/Headquarters

What happened to Alexion stock?

Trading of the new AstraZeneca shares on Nasdaq Stockholm is expected to commence on 22 July 2021. The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.